WuXi PharmaTech’s genomics clinical laboratory in Shanghai has received CLIA (Clinical Laboratory Improvement Amendments) certification following a successful inspection by the Centers for Medicare and Medicaid Services of the U.S. Department of Health and Human Services. WuXi’s lab is currently the only CLIA-certified clinical lab in China and allows WuXi’s genomics lab to undertake certain clinical trial gene sequencing projects.
 
CLIA standards relate to all clinical lab testing on specimens derived from humans in the U.S. to give information for the assessment, diagnosis, prevention, and treatment of disease. CLIA aims to ensure the accuracy, reliability and timeliness of test results regardless of where the test is performed.
 
“We are excited about the addition of CLIA-certified clinical laboratory testing to our suite of service offerings,” said Dr. Ge Li, chief executive officer of WuXi AppTec. “WuXi is dedicated to the highest operational and quality standards. Our CLIA certification is an important milestone in realizing our vision to build an open-access technology and capability platform that enables anyone and any company to discover and develop therapeutic products to benefit patients.”